
CISPOLY: DNA methylation tests for gynecologic cancers
Guarding women's health through innovative epigenetic technology
A pioneer in early screening & diagnosis of gynecologic tumors
Advancing DNA methylation technology to break new ground in non-invasive early detection.
Founded in 2020 and headquartered in the Beijing Daxing Biomedical Industry Base, CISPOLY is a technology-driven enterprise dedicated to advancing health through innovation. As a pioneer in early screening and diagnosis of gynecologic cancers, CISPOLY is a certified National and Zhongguancun High-Tech Enterprise, focusing on the R&D, manufacturing, and commercialization of early screening and diagnostic products for women's cancers and related diseases, along with automated testing equipment.
English registered name: Beijing OriginPoly Bio-Tec Co., Ltd. (also written as "Beijing Origin-Poly Bio-Tec Co., Ltd." in academic affiliations). Brand: CISPOLY / 聚禾生物.
Driven by innovative technology
Our Journey
CISPOLY founded, headquartered in the Beijing Daxing Biomedical Industry Base
CISCER® received NMPA registration (No. 20233400253)
CISENDO® received NMPA registration (No. 20243402610) — the world's first non-invasive endometrial cancer screening launched
CISOVA® received NMPA registration (No. 20253402443) — China's first ovarian cancer methylation test launched; recognized as a Beijing SRDI (Specialized, Refined, Differential, Innovative) Enterprise
